CureVac sues BioNTech over Covid vaccine technology

CureVac, the German pharmaceutical company, said Tuesday (July 6th) that it is suing BioNTech, its rival in the pharmaceutical sector, for patent infringement. The patent infringement lawsuit for them concerns the mRNA technology to develop the Comirnaty vaccine against the coronvirus.

CureVac said in a statement that it intends to “enforce its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which has contributed to the development of the vaccine. covid-19”.

The lawsuit against Mainz-based BioNTech and two of its subsidiaries will seek “fair compensation” for infringement of intellectual property rights, the company said.

BioNTech developed Comirnaty jab with the American pharmaceutical company Pfizer. It was the first Covid-19 vaccine to be approved in the West. It has since become one of the most widely used vaccines in the world.

Tübingen-based CureVac was founded 22 years ago by mRNA pioneer Ingmar Hoerr.

He has since patented core technology “related to the design, delivery and manufacture of mRNA” which he says has “significantly contributed to the development of safe and effective Covid-19 vaccines”.

CureVac said that as an “early pioneer in mRNA technology” it had backed “decades of scientific research and innovation” behind the shots.

BioNTech said in a statement that its work is original and that it “will vigorously defend it against all allegations of patent infringement.”

“We are aware that it is not unusual for other companies in the pharmaceutical industry, having witnessed the success of Comirnaty, to now suggest that the vaccine potentially infringes their intellectual property rights,” he said. declared.

CureVac said it does not anticipate any legal action that could impede the production, sale or distribution of the Comirnaty vaccine.

(With agency contributions)

You can now write for and be part of the community. Share your stories and opinions with us here.


#CureVac #sues #BioNTech #Covid #vaccine #technology

Post expires at 7:06pm on Friday July 15th, 2022